Do we still need to develop new imaging biomarkers of dopamine denervation for Parkinson's disease?

Experimental Neurology

Volumn 233, Issue 1, 2012, Pages 118-120

  Pavese, Nicola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2BETA CARBOMETHOXY 3BETA (4 CHLOROPHENYL) 8 (2 FLUOROETHYL)NORTROPANE; 6 FLUORODOPA F 18; BIOLOGICAL MARKER; CARBON 11; DIHYDROTETRABENAZINE; DOPAMINE; DOPAMINE TRANSPORTER; FLUORINE 18; NORADRENALIN TRANSPORTER; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

BINDING AFFINITY; BIOAVAILABILITY; BRAIN REGION; DENERVATION; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NOTE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUORINE RADIOISOTOPES; MPTP POISONING; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY;

EID: 84856229179     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.10.008     Document Type: Note

References (16)

1. Davis M.R., Votaw J.R., Bremner J.D., Byas-Smith M.G., Faber T.L., Voll R.J., Hoffman J.M., Grafton S.T., Kilts C.D., Goodman M.M. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J. Nucl. Med. 2003, 44:855-861.
2. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114:2283-2301.
3. Firnau G., Sood S., Chirakal R., Nahmias C., Garnett E.S. Cerebral metabolism of 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine in the primate. J. Neurochem. 1987, 48:1077-1082.
4. Garnett E.S., Firnau G., Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983, 305:137-138.
5. Goodman M.M., Keil R., Shoup T.M., Eshima D., Eshima L., Kilts C., Votaw J., Camp V.M., Votaw D., Smith E., Kung M.P., Malveaux E., Watts R., Huerkamp M., Wu D., Garcia E., Hoffman J.M. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J. Nucl. Med. 1997, 38:119-126.
6. Goodman M.M., Kilts C.D., Keil R., Shi B., Martarello L., Xing D., Votaw J., Ely T.D., Lambert P., Owens M.J., Camp V.M., Malveaux E., Hoffman J.M. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl. Med. Biol. 2000, 27:1-12.
7. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopamine nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47:493-503.
8. Masilamoni G., Votaw J., Howell L., Villalba R.M., Goodman M., Voll R.J., Stehouwer J., Wichmann T., Smith Y. (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp. Neurol. 2010, 226:265-273.
9. Morrish P.K., Sawle G.V., Brooks D.J. An 18F-dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
10. Nagai Y., Obayashi S., Ando K., Inaji M., Maeda J., Okauchi T., Ito H., Suhara T. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse 2007, 61:809-819.
11. Nikolaus S., Antke C., Kley K., Poeppel T.D., Hautzel H., Schmidt D., Müller H.W. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev. Neurosci. 2007, 18:439-472.
12. Okamura N., Villemagne V.L., Drago J., Pejoska S., Dhamija R.K., Mulligan R.S., Ellis J.R., Ackermann U., O'Keefe G., Jones G., Kung H.F., Pontecorvo M.J., Skovronsky D., Rowe C.C. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J. Nucl. Med. 2010, 51:223-228.
13. Pavese N., Kiferle L., Piccini P. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 4):S33-S37.
14. Pirker W., Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P., Brücke T. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J. Nucl. Med. 2000, 41:36-44.
15. Ribeiro M.J., Vidailhet M., Loch C., Dupel C., Nguyen J.P., Ponchant M., Dolle F., Peschanski M., Hantraye P., Cesaro P., Samson Y., Remy P. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol. 2002, 59:580-586.
16. Votaw J.R., Howell L.L., Martarello L., Hoffman J.M., Kilts C.D., Lindsey K.P., Goodman M.M. Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. Synapse 2002, 44:203-210.